The FDA on June 24, 2020 approved KEYTRUDA® for patients with recurrent or metastatic cutaneous Squamous Cell Carcinoma (cSCC) that is not curable by surgery or radiation. KEYTRUDA® is a product of Merck & Co., Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
